Back to Search
NIKITA RAJE, MD
MD
Pediatrics Physician
NPI: 1578765921IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
4301087074(MI)
Pediatrics PhysicianPrimary
Pediatrics
Code: 208000000X
4301087074(MI)2011001493(MO)04-34964(KS)
Education
OTHER
Class of 2002
Research & Publications (20)
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.
PMID 19270264·Blood·2009
8-other
Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression.
PMID 19652203·Blood·2009
7-preclinical
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
PMID 19509164·Clin Cancer Res·2009
7-preclinical
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
PMID 19151776·Leukemia·2009
7-preclinical
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
PMID 19436050·Blood·2009
7-preclinical
Ascorbic acid inhibits antitumor activity of bortezomib in vivo.
PMID 19369963·Leukemia·2009
7-preclinical
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.
PMID 19417213·Blood·2009
7-preclinical
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.
PMID 18948577·Blood·2009
7-preclinical
The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement.
PMID 18509352·Leukemia·2008
8-other
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
PMID 18596740·Leukemia·2008
2-rct
Higher risk factor burden and worse outcomes in urban carotid endarterectomy patients.
PMID 18688001·Stroke·2008
8-other
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma.
PMID 18728702·Ther Clin Risk Manag·2008
8-other
Thalidomide and lenalidomide: Mechanism-based potential drug combinations.
PMID 18452080·Leuk Lymphoma·2008
6-review
Case records of the Massachusetts General Hospital. Case 9-2008. A 65-year-old woman with a nonhealing ulcer of the jaw.
PMID 18354107·N Engl J Med·2008
5-case
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
PMID 18397345·Br J Haematol·2008
7-preclinical
Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.
PMID 18413829·Clin Cancer Res·2008
8-other
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.
PMID 18219387·J Clin Invest·2008
7-preclinical
Neurological manifestations of Waldenström macroglobulinemia.
PMID 18813229·Nat Clin Pract Neurol·2008
6-review
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model.
PMID 17908986·Clin Cancer Res·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 2401 GILLHAM RD
KANSAS CITY, MO 64108 - Phone
- (816) 234-3000
Quick Facts
- NPI
- 1578765921
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 4
- Locations
- 2
- Years in Practice
- 24
- Publications
- 20
Are you this provider?
Claim Your Profile